Management of chronic hepatitis B: consensus guidelines.
- 1 June 2007
- journal article
- review article
- Vol. 21, 5C-24C
Abstract
The present document presents the proceedings of the consensus development conference on the management of viral hepatitis held in January 2007 under the auspices of the Canadian Association for the Study of the Liver and the Association of Medical Microbiology and Infectious Disease Canada. Several new agents have become available since the last such document was published in 2004, and new information has become available to help assess risk of adverse outcomes and who should be treated. In addition, the participants at the meeting identified a number of structural barriers that exist uniquely in Canada and that prevent physicians from properly managing their patients. The conference discussed the selection of patients for treatment and the drugs that can be used to treat these patients, as well as the treatment of hepatitis B in special populations. The present document should be read in conjunction with the companion document on the management of chronic hepatitis C.Keywords
This publication has 143 references indexed in Scilit:
- Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: A two-year studyJournal of Hepatology, 2005
- Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis BNew England Journal of Medicine, 2004
- Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to LamivudineAntimicrobial Agents and Chemotherapy, 2004
- Assessing the risk of birth defects associated with antiretroviral exposure during pregnancyAmerican Journal of Obstetrics and Gynecology, 2004
- Interferon-α for HBeAg-positive chronic hepatitis BJournal of Hepatology, 2003
- Serum α-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV statusJournal of Hepatology, 2001
- Lamivudine as Initial Treatment for Chronic Hepatitis B in the United StatesNew England Journal of Medicine, 1999
- Treatment of hepatitis B virus-associated membranous nephropathy with recombinant alpha-interferonKidney International, 1995
- Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriersArchives of internal medicine (1960), 1990
- Determinants for hepatitis B e antigen clearance in chronic type B hepatitisLiver International, 1984